MP66-02 SURVIVAL ANALYSIS OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA UNDERGOING CYTOREDUCTIVE NEPHRECTOMY WITH OR WITHOUT A NEOADJUVANT TYROSINE KINASE INHIBITOR

You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) II1 Apr 2018MP66-02 SURVIVAL ANALYSIS OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA UNDERGOING CYTOREDUCTIVE NEPHRECTOMY WITH OR WITHOUT A NEOADJUVANT TYROSINE KINASE INHIBITOR Jing Zhi Lo, Peter Sunaryo, David Paulucci, and Ketan Badani Jing Zhi LoJing Zhi Lo More articles by this author , Peter SunaryoPeter Sunaryo More articles by this author , David PaulucciDavid Paulucci More articles by this author , and Ketan BadaniKetan Badani More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.1874AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Metastatic renal cell carcinoma portends a poor prognosis with a 5-year overall survival (OS) of only 8%. We evaluated whether neoadjuvant tyrosine kinase inhibitors (TKI) prolongs OS in patients undergoing cytoreductive nephrectomy (CN) using the National Cancer Database (NCDB). METHODS The NCDB was utilized to identify 2,314 patients who underwent CN for metastatic renal cell carcinoma between 2006 and 2013. OS was compared between patients who received CN alone (n=2,131, 92.1%) and those who received neoadjuvant TKI within 6 months prior to CN (n=183, 7.9%). Inverse probability of treatment weighted (IPTW) cox proportional hazards regression models were used to compare OS, adjusting for patient selection factors. RESULTS OS at 12, 24 and 36 months were 62.2%, 49.2% and 38.5%, respectively (median follow-up 17.1 months, IQR 4.4-35.8 months). Neoadjuvant TKI prior to CN was associated with improved OS up to 24 months (HR=0.79; 95% CI=0.66, 0.94; p=0.007). However, after 24 months, the benefit of TKI treatment disappeared (HR=1.39; 95% CI=0.99, 1.97; p=0.060). CONCLUSIONS Use of neoadjuvant TKI in the cytoreductive nephrectomy setting was associated with improved OS up to 24 months. However, long term benefit remains unproven and will require further investigation. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e867 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Jing Zhi Lo More articles by this author Peter Sunaryo More articles by this author David Paulucci More articles by this author Ketan Badani More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...